1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Retrospective evaluation of the predictive value of tumour burden at baseline [
68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.
(
- Contribution to journal › Article
- 2023
-
Mark
AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
(
- Contribution to journal › Article
- 2022
-
Mark
Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET
(
- Contribution to journal › Article
- 2019
-
Mark
A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors
(
- Contribution to journal › Article